key: cord-0986912-szzvo3u2
authors: Ko, Humphrey H T
title: Transmissibility of SARS-CoV-2 among fully vaccinated individuals
date: 2021-12-22
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00765-9
sha: 0202d9ba06f131c492ad56d65b80cc680a349191
doc_id: 986912
cord_uid: szzvo3u2

nan

Appendix (table S1): Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) amino acid mutations that characterise variants of interest or concern.

This table summarises current known SARS-CoV-2 amino acid mutations that characterise variants of interest or concern described by Harvey and colleagues, 1 and is not meant to be exhaustive.

ACE2=angiotensin converting enzyme 2, mAb=monoclonal antibody.

Deletion Δ69-70 • Associated with increased infectivity.

• Reduced neutralisation titres.

Deletion Δ141-144 • Abolishes binding of neutralising antibody 4A8.

• Abolishes binding of neutralising antibody 4A8.

Deletion Δ243-244 • Abolishes binding of neutralising antibody 4A8.

• Resistant to neutralisation by mAb.

Deletion ΔH69-V70

• Associated with immune escape in immunocompromised individuals treated with convalescent plasma.

• Abolished neutralisation by a range of neutralising antibodies.

• Affected neutralising activity of several mAbs.

• Increased infectivity and transmissibility.

• Decreased susceptibility to neutralising antibodies.

• Significantly reduced neutralisation titres.

• Reduced neutralisation by mAb 2489.

• Resistant to neutralisation.

• Resistant to neutralisation.

K150E, K150Q, K150R, and K150T

• Resistant to neutralisation by mAb.

• Moderately decreased ACE2-binding affinity.

• Reduced neutralisation titres.

• Resistant to neutralization by mAb.

• Reduced neutralisation by some antibodies.

• Likely to affect antibody binding.

• Reduced neutralisation by several mAbs and convalescent plasma.

• Resistant to neutralisation by mAb.

• Increased ACE2 receptor binding affinity • Reduced neutralising activity of mAbs in convalescent sera.

• Increased ACE2-binding affinity.

• Modestly reduced neutralisation by mAbs.

• Strong evidence of adaptation, further experiments required to determine its impact.

• Likely to affect antibody binding.

• Affected neutralising activity of several mAbs.

• Resistant to neutralisation by mAb.

• Resistant to neutralisation by mAb.

• S477N = Increased affinity for ACE2 (lesser extent compared with N439K and N501Y).

• Resistant to neutralisation by mAb.

• Increased ACE2 binding affinity.

• Modestly reduced neutralisation by mAbs.

SARS-CoV-2 variants, spike mutations and immune escape